Using X-ray crystallography, we have determined the structure of the first two short consensus repeats (SCRs) of human complement receptor (CR) 2 in complex with C3d. These studies revealed: (i) a primary site of interaction for C3d within SCR2 of CR2, (ii) a hydrophobic patch holding SCRl to SCR2 in a rigid V-shape, (iii) a dimer formed by interactions between SCRl of each molecule, (iv) several non-linear sequences on C3d that interact with CR2 and (v) mutations of C3d amino acids within the co-crystal interface that resulted in decreased binding. In addition, a polymorphism that results in decreased C3d binding and introduces a new glycosylation site predicted to disrupt the dimer interface was found in the New Zealand White autoimmune mouse strain. Although the co-crystal complex results are in agreement with a subset of prior studies, our additional findings, which demonstrate an extended SCR1-SCR2 structure in solution and differences in the kinetics of ligand-receptor interactions with longer forms of CR2, have suggested a more complex receptor-ligand interaction. T o characterize this interaction further, several approaches directed at the determination of solution phase interactions as well as the analysis of the three-dimensional structure of CR2 alone and key CR2 mutants will be necessary.
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Background
Human complement receptor (CR) 2 expression Human CR2 is a receptor that plays an integral role in the immune system (reviewed in [1, 2] ). Cells which express CR2 include mature B-cells, thymocytes, a subset of CD4+ and CD8+ peripheral T-cells, follicular dendritic cells (FDCs), basophils, mast cells, keratinocytes and epithelial cells. Relative CR2 surface expression is primarily controlled at the level of transcription by the proximal promoter, while cell and lineage specificity is regulated by an intronic regulatory mechanism [3-51.
CR2 ligands
CR2 has three well-characterized classes of ligands. These include the C3 activation fragments iC3b, C3dg and C3d [6, 7] , Epstein-Barr virus (EBV) via the surface glycoproteins gp350 and gp220 [8, 9] , and the immunomodulatory protein CD23 [lo] . C3 activation fragments are covalently attached to antigens or to immune complexes following complement activation, thus allowing for high-affinity interactions with CR2. 
CR2-deficient mice
Support for a critical role of CR2 in the immune response has been provided by results in mice that are deficient in CR2 (as well as CR1). This 'knockout ' demonstrates substantial defects in antigen-specific, T-cell-dependent humoral immune responses [31-331, as well as defects in B-cell memory [34, 35] .
Role of CR2 in self-tolerance
In addition to a critical role in the immune response to foreign antigens, recent studies have suggested that CR2 may also play a role in maintaining tolerance to self antigens. T h e mechanism may be related to self-antigen capture or presentation in the bone marrow, or to enhancing signalling of auto-reactive B-cells that normally results in deletion [36] . Altered expression of human CR2 in patients with systemic lupus erythematosus (SLE) [37] and mouse models of S L E [38] suggests that this function of CR2 may be pathophysiologically important. T h e identification of a highly informative mouse CR2 mutant affecting ligand binding and signal transduction has also provided insight into this role of CR2. T h e major murine lupus susceptibility locus, SZeZ, corresponds to three loci that independently affect loss of tolerance to chromatin in the NZM2410 (New Zealand Mixed) mouse. In initial mapping studies, the congenic interval corresponding to Slelc was found to contain CrZ [39] . During a series of studies to determine whether Cr2 might be the lupus susceptibility gene in this interval, a singlenucleotide polymorphism that introduces a novel glycosylation site, resulting in proteins of greater molecular mass, was found. Of interest, this polymorphism is located in the SCR1-SRC2 ligand-binding domain and results in reduced ligand binding and receptor-mediated cell signalling [39] . Importantly, molecular modelling based on the CR2-C3d co-crystal structure revealed that this glycosylation is predicted to interfere with receptor dimerization. In addition to strongly supporting the role of Cr2 as a lupus susceptibility gene in this model, these studies have provided the strongest evidence to date that receptor dimerization is an important and relevant event in vivo.
In addition to SLE, CR2 expression is also required to develop autoimmunity to cardiac myosin in a murine model of autoimmune myocarditis, a phenotype that is likely to be related to changes in both cellular and humoral immune responses [40] . CR2 as a target of alternative pathway complement activation and C3 deposition CR2 on B-cells serves an intriguing additional function as a preferential site for covalent attachment of C3 fragments generated through the alternative pathway when iC3b binds to the SCRI-SCR2 domain [57] . T h e biological importance of this observation is unclear, although the role may be, in part, to enhance adhesion of B-cells with CR2-attached C3 fragments to CR2-expressing T-cells [58] . Of relevance to this proposal is the fact that the activated C3 fragments are apparently bound to SCR(s) at the mid-portion of CR2 [59] .
CR2 as the EBV receptor

CR2 as a mediator of HIV-I infection of naive T-cells through binding of C3 fragmentcontaining viral immune complexes
On FDCs, CR2 serves as a receptor for C3-bound immune complexes and can therefore mediate retention of antigens for prolonged periods [60] . One result of this is the retention on FDCs of highly infectious HIV-1 that are present as C3-bound immune complexes [61] that can be released from germinal centre FDCs in vitro by inhibition of C3-CR2 binding [62] . Freshly isolated B-cells from the peripheral blood and lymph nodes of patients with AIDS have also been shown to efficiently transfer CR2-bound immune complexes containing HIV-1 from their surfaces, which can then infect nai've T-cells using a CD4-dependent mechanism [63] . In addition, CR2-expressing thymocytes and peripheral T-cells can also be infected with HIV-1 immune complexes containing C3 ligands through this receptor [64] .
Approaches to understanding CR2 structure-function relationships
Surface plasmon resonance studies Studies performed a decade ago demonstrated that the SCRl-SCR2 domain of CR2 is both necessary and sufficient to mediate high-affinity interactions with C3d [65, 66] , and that this domain also interacts with EBV gp350 and CD23 [67] in overlapping, but non-identical sites. These studies have shown that both SCRl and SCR2 are required for interactions to occur. More recently, the interactions with C3d of the SCRl-SCR2 domain alone in comparison with longer forms of CR2 containing additional SCRs have been reexamined using surface plasmon resonance. One of the most interesting findings of these studies has been that the binding kinetics of the SCR1-SCR2 domain with C3dg are markedly different than those of the SCRl-SCR15 domain when interacting [68] . Although the K , values for the interactions were indistinguishable, the association and dissociation of SCRl-SCR15 were approx. 10-fold slower than those of the SCR1-SCR2 domain. These differences were not due to differences in glycosylation, ligand density, or factors such as mass transfer. Therefore, despite the evidence that the major binding interaction is clearly within the SCRl-SCR2 domain, SCRs outside of the SCRl-SCR2 domain influence binding, either by obstruction of the binding site through a folded-back conformation, through direct ligand contacts, through a co-operativity effect, or by a combination of effects. Owing to these findings, in addition to the presence of three additional relatively long, eight-amino-acid-containing linkers in this membrane-proximal region, an additional CD23-binding site within SCRs 5-8, and possibly sites for interaction with iC3b, it will be important to study the role and structure of the SCR3-SCR15 domain of CR2.
X-ray crystallography X-ray crystallographic approaches have also been directed at this interaction, and recently the structure of the CR2 SCR1-SCR2 domain was solved in complex with C3d at a resolution of 2.0 A (1 A = 0.1 nm) [69] . T h e structure revealed many unanticipated features: (i) only SCR2 contacts C3d, (ii) extensive SCRl-SCR2 side-by-side packing in a folded-back structure, held together by hydrophobic bonds that are contributed by each of the SCRl and SCR2 domains as well as by the highly structured linker, (ii) the presence of extensive main-chain, rather than side-chain, interactions between C3d and CR2, (iv) receptor contact sites on C3d that were not previously predicted by mutagenesis of C3d (the underlying hypothesis in those particular studies that CR2 would bind in a negatively charged, concave region [70, 71] was found not to be true) and (v) a CR2-CR2 dimer formed by contacts between the SCRl domain of each molecule.
Importantly, although several features, such as the lack of major SCRl-C3d contacts, were not predicted based on previous studies, several experimental approaches were used to validate the co-crystal structure. First, mutagenesis of C3d at the sites predicted in the co-crystal structure markedly decreased binding to CR2 [69] . Secondly, previous studies using CR2-derived peptides to block CR2-C3 interactions identified one highly inhibitory peptide [72] that included the amino acid sequence from the C3d contact site within SCR2 in the CR2-C3d co-crystal. Thirdly, a new mAb was created (mAb 171), the most highly inhibitory of the new set, which recognized a peptide derived from the CR2 portion of the SCR2ZC3d interface [73] . Finally, substantial support for the relevance of the SCR1-SCRI dimer was provided by the identification of the polymorphic CR2 variant in mouse that binds C3d substantially less well, as described above [39] .
Solution studies
Despite the determination of the co-crystal structure of CR2 with C3d, there is evidence to support the hypothesis that certain features of the solution structure may well be different from the static ligand-bound structure observed in the co-crystal structure. For example, the identical SCR1-SCR2 domain used for co-crystal studies was subjected to analytical ultracentrifugation ; by sedimentation equilibrium, the domain itself was determined to be monomeric in physiological buffers [68] . By sedimentation velocity, the sedimentation coefficient was determined by the time-derivative method to be 1.25 S. Comparison of this value with those calculated the SCR1-SCR2 domain in an extended structure (1.36 S) and a U-shaped structure (1.66 S) revealed that the two SCR domains were predicted to be extended in solution rather than folded-back, as seen in the co-crystal structure 1681.
Additional approaches to a better understanding of CR2 structure-function relationships X-ray and neutron scattering Owing to the results presented above, further studies using alternate techniques will be necessary to provide more insight into this ligandreceptor interaction. One such approach employs X-ray and neutron scattering, together with homology modelling, as recently successfully applied to the related protein Factor H [74] . X-ray and neutron scattering complement each other: in application to proteins such as CR2, X-rays detect the glycoprotein in a high positive solvent contrast, while neutrons use heavy water to make observations in a high negative contrast, thereby eliminating effects arising from internal glycoprotein inhomogeneities. X-ray curves are usually obtained with better statistics, while neutron curves are unaffected by possible radiation damage as a key control. X-ray curves detect hydrated structures, while neutron curves indicate dry structures. Both techniques have the major advantage that the curves can be directly calculated from known atomic structures. T h e structural resolution is improved to a medium resolution (5-1OA) by the use of well justified, tight constraints that are used to construct molecular models in order to account for the scattering curves. There are two main constraints : (i) the use of known atomic structure(s) or homology models for the domains, and (ii) use of modelled steric connections between the domains based on their known sequences.
Importantly, neutron and X-ray scattering curves provide information on the averaged full, multi-domain structure of proteins in solution. These techniques are ideal for proteins such as CR2 that are too large to be crystallized intact in 15-or 16-SCR full-length forms (for reasons of interdomain flexibility or high glycosylation) and thus provide substantial insight into structures that otherwise would be completely unavailable [ 7 5,761.
NMR spectroscopy
In addition to scattering and homology modelling, the application of N M R spectroscopy, a key tool for structural studies of biological molecules in solution, will be necessary. This technique allows the study of three-dimensional structures and flexibility at atomic resolution, enabling the relationship between dynamics and function to be defined. Using three-and four-dimensional NMR experiments and isotope-labelling, it is currently possible to solve the structures of multi-domain proteins and large complexes. NMR can be used to map binding sites for both weak and strong interactions by analysis, for example, of chemical shifts, coupling constants, and line shapes [77] .
Although only X-ray crystallography can reveal the structures of large complexes at high resolution, NMR is uniquely able to provide information about domain-domain orientations and linker flexibility, and weak (albeit physiologically critical) interactions. This is relevant to CR2 analysis because the linker between SCRl and SCR2 of CR2 is unusually long, and the predicted SCR1-SCR1 dimer is weak, its formation being perhaps dependent on proximal presentation on the membrane surface.
Important new NMR technologies have emerged in the past few years that will have an impact on the successful completion of these studies. Improvements in field strength lead to a significantly greater resolving power, particularly with > 800 MHz magnets. T h e extra dispersion and sensitivity is particularly important when the NMR method is extended to tackle multi-domain systems, large protein-ligand complexes and membrane-associated proteins such as those studied here. Ultra-high field NMR spectrometry provides much higher sensitivity and resolution of the NMR signals in part due to the recent development of transverse relaxation optimized Figure I A multiple-state model of CR2 SCRI-SCR2 domains and their interactions
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